Literature DB >> 19669218

Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer.

Natasa Anastasov1, Margit Klier, Ina Koch, Daniela Angermeier, Heinz Höfler, Falko Fend, Leticia Quintanilla-Martinez.   

Abstract

RNA interference is a powerful tool for the functional analysis of proteins by specific gene knockdown. In this study, we devised a rapid and efficient way to screen suitable siRNA sequences and subsequently employ them for specific gene knockdown in usually hard-to-transfect lymphoid cell lines, using a self-inactivating lentiviral vector. Two proteins with different half-lives were chosen, cyclin D1 and STAT3. A specific lacZ reporter fusion assay was used to identify highly effective siRNA sequences. Only siRNA molecules with more than 85% of knockdown efficiency were selected for the generation of lentiviral transfer vectors. Transduction rates of 75-99% were achieved in the lymphoma cell lines Granta 519 (mantle cell lymphoma), Karpas 299, and SUDHL-1 (anaplastic large T cell lymphoma), as demonstrated by green fluorescent protein expression in fluorescence-activated cell sorting analysis. The high level of transduction efficiency allows RNA interference studies to be performed on transduced cells without further manipulation, such as cell sorting or cloning. The LacZ reporter system together with the lentivirus technology is a very important tool in the hematology field, which enables experiments in lymphoid cells that were not possible before.

Entities:  

Year:  2008        PMID: 19669218      PMCID: PMC2713496          DOI: 10.1007/s12308-008-0020-x

Source DB:  PubMed          Journal:  J Hematop        ISSN: 1865-5785            Impact factor:   0.196


  25 in total

1.  Factors influencing the titer and infectivity of lentiviral vectors.

Authors:  Aaron C Logan; Sarah J Nightingale; Dennis L Haas; Gerald J Cho; Karen A Pepper; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2004-10       Impact factor: 5.695

2.  Efficient gene transfer into primary human natural killer cells by retroviral transduction.

Authors:  Hayrettin Guven; Kyriakos V Konstantinidis; Evren Alici; Alar Aints; Manuchehr Abedi-Valugerdi; Birger Christensson; Hans-Gustaf Ljunggren; M Sirac Dilber
Journal:  Exp Hematol       Date:  2005-11       Impact factor: 3.084

3.  Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells.

Authors:  Li-fang Gao; De-qi Xu; Lian-ji Wen; Xing-yi Zhang; Yue-ting Shao; Xue-jian Zhao
Journal:  Acta Pharmacol Sin       Date:  2005-03       Impact factor: 6.150

4.  Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.

Authors:  Steffen Schubert; Arnold Grünweller; Volker A Erdmann; Jens Kurreck
Journal:  J Mol Biol       Date:  2005-05-13       Impact factor: 5.469

Review 5.  RNA interference in biology and disease.

Authors:  Carol A Sledz; Bryan R G Williams
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

6.  Effect of target secondary structure on RNAi efficiency.

Authors:  Yu Shao; Chi Yu Chan; Anil Maliyekkel; Charles E Lawrence; Igor B Roninson; Ye Ding
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

7.  Transient transfection of primary T helper cells by particle-mediated gene transfer.

Authors:  H Huang; C Pannetier; J Hu-Li; W E Paul
Journal:  J Immunol Methods       Date:  1998-06-01       Impact factor: 2.303

8.  Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

Authors:  J A Diehl; F Zindy; C J Sherr
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

9.  NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.

Authors:  Leticia Quintanilla-Martinez; Stefania Pittaluga; Cornelius Miething; Margit Klier; Martina Rudelius; Theresa Davies-Hill; Natasa Anastasov; Antonio Martinez; Angelica Vivero; Justus Duyster; Elaine S Jaffe; Falko Fend; Mark Raffeld
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

10.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.

Authors:  Roberto Chiarle; William J Simmons; Honjying Cai; Girish Dhall; Alberto Zamo; Regina Raz; James G Karras; David E Levy; Giorgio Inghirami
Journal:  Nat Med       Date:  2005-05-15       Impact factor: 53.440

View more
  16 in total

1.  Protease activated receptor-1 deficiency diminishes bleomycin-induced skin fibrosis.

Authors:  JanWillem Duitman; Roberta R Ruela-de-Sousa; Kun Shi; Onno J de Boer; Keren S Borensztajn; Sandrine Florquin; Maikel P Peppelenbosch; C Arnold Spek
Journal:  Mol Med       Date:  2014-09-18       Impact factor: 6.354

2.  EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

Authors:  Janine Schmidt; Irina Bonzheim; Julia Steinhilber; Ivonne A Montes-Mojarro; Carlos Ortiz-Hidalgo; Wolfram Klapper; Falko Fend; Leticia Quintanilla-Martínez
Journal:  Lab Invest       Date:  2017-06-05       Impact factor: 5.662

3.  miRNA-155 modulates the malignant biological characteristics of NK/T-cell lymphoma cells by targeting FOXO3a gene.

Authors:  Wei-Guo Ji; Xu-Dong Zhang; Xiang-Dong Sun; Xiang-Qi Wang; Bao-Ping Chang; Ming-Zhi Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

4.  C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.

Authors:  Natasa Anastasov; Irina Bonzheim; Martina Rudelius; Margit Klier; Therese Dau; Daniela Angermeier; Justus Duyster; Stefania Pittaluga; Falko Fend; Mark Raffeld; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

5.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

6.  Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies.

Authors:  H Ehrhardt; L Pannert; S Pfeiffer; F Wachter; E Amtmann; I Jeremias
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

7.  Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis.

Authors:  H Ehrhardt; F Wachter; M Grunert; I Jeremias
Journal:  Cell Death Dis       Date:  2013-06-06       Impact factor: 8.469

8.  Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.

Authors:  Irina Bonzheim; Martin Irmler; Margit Klier-Richter; Julia Steinhilber; Nataša Anastasov; Sabine Schäfer; Patrick Adam; Johannes Beckers; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells.

Authors:  Nataša Anastasov; Ines Höfig; Iria Gonzalez Vasconcellos; Kristina Rappl; Herbert Braselmann; Natalie Ludyga; Gert Auer; Michaela Aubele; Michael J Atkinson
Journal:  Radiat Oncol       Date:  2012-12-05       Impact factor: 3.481

10.  Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas.

Authors:  Misu Lee; Ilaria Marinoni; Martin Irmler; Tsambika Psaras; Jürgen B Honegger; Rudi Beschorner; Natasa Anastasov; Johannes Beckers; Marily Theodoropoulou; Federico Roncaroli; Natalia S Pellegata
Journal:  Acta Neuropathol       Date:  2013-06-12       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.